Wells Fargo Maintains Overweight on Keros Therapeutics, Lowers Price Target to $18
Wells Fargo analyst Benjamin Burnett maintains Keros Therapeutics (NASDAQ:KROS) with a Overweight and lowers the price target from $20 to $18.
Stocks · News reference
Keros Therapeutics To Receive $20M Milestone Payment From Takeda Under Elritercept Licensing Terms After Dosing First Patient In The ELRiSE MDS Trial
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share
8-K filing — Keros Therapeutics, Inc. (KROS)
Filed: 2026-08-03 AccNo: 0001664710-26-000050 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Takeda Secures FDA Approval For First-In-Class Blood Cancer Drug
The FDA approved Takeda's MIMRYLO to treat erythrocytosis in adults with polycythemia vera, offering an effective new hematocrit control.
Takeda’s ORZEYFUL Wins Japan Approval For Narcolepsy Type 1 After Phase 3 Studies Show Significant Improvements Across Evaluated Symptoms
Royalty Pharma Locks in $100M Zealand Pharma Funding Pact for Blood Disorder Drug
Royalty Pharma will pay Zealand Pharma $100 million for economic rights tied to rusfertide, with FDA action expected in Q3 of 2026.